CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies
Jang Won Son, Sungrae Kim
Diabetes Metab J. 2015;39(5):373-383.   Published online October 22, 2015
DOI: https://doi.org/10.4093/dmj.2015.39.5.373

Excel Download

Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies
Diabetes & Metabolism Journal. 2015;39(5):373   Crossref logo
Link1 Link2 Link3

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes
Diabetes and Vascular Disease Research. 2015;12(3):154-163   Crossref logo
Link1 Link2 Link3

Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus
Diabetes Research and Clinical Practice. 2016;116:171-182   Crossref logo
Link1 Link2

Evaluation of large-scale clinical trials on cardiovascular disease risk in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase 4 inhibitors and a new class of drugs
Journal of Diabetes Investigation. 2017;8(5):633-634   Crossref logo
Link1 Link2

The Effects of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Disease Risks in Type 2 Diabetes Mellitus
Journal of Diabetes Research. 2013;2013:1-6   Crossref logo
Link1 Link2 Link3

THEEFFECT OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS ON CARDIOVASCULAR DISEASE RISK IN TYPE 2 DIABETES MELLITUS
International Journal of Pharmacy and Pharmaceutical Sciences. 2016;9(1):254   Crossref logo
Link1 Link2 Link3

Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?
Diabetes and Vascular Disease Research. 2019;16(4):303-309   Crossref logo
Link1 Link2 Link3

Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second- and third-line antidiabetic drugs in patients with type 2 diabetes
British Journal of Clinical Pharmacology. 2017;83(7):1556-1570   Crossref logo
Link1 Link2

MO38-5 Dipeptidyl peptidase-4 inhibitors and risk of gall bladder cancer in type 2 diabetes patients: A meta-analytic synthesis
Annals of Oncology. 2021;32:S324   Crossref logo
Link1 Link2

Diabetes and Cardiovascular Risk: Are Dipeptidyl Peptidase-4 Inhibitors Beneficial?
Hospital Pharmacy. 2014;49(8):697-701   Crossref logo
Link1 Link2 Link3